This designation has been awarded for the treatment of AMHR2-expressing ovarian cancers, exclusive of AMHR2-expressing fallopian tube cancers and primary peritoneal cancers
GamaMabs Pharma receives Orphan Drug Designation from US FDA for lead compound GM102
